# Zevra (ZVRA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ZVRA
## Company Profile
- Ticker: ZVRA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 12.54 USD
- Market cap: 643172113.9200001 USD
- Last updated: 2026-09-03
## Business Overview
### Rare-Disease Commercial Platform
Zevra Therapeutics is a commercial-stage company focused on therapies for rare diseases. Its operating model combines direct commercialization, global patient-access programs and development of treatments for small, underserved populations.
### MIPLYFFA
MIPLYFFA, or arimoclomol, is FDA approved with miglustat for neurological manifestations of Niemann-Pick disease type C in patients two years and older. Zevra also operates a global expanded-access program and has submitted a European marketing application.
### OLPRUVA
OLPRUVA is an approved formulation of sodium phenylbutyrate for certain urea-cycle disorders, giving Zevra a second commercial product in inherited metabolic disease.
### Celiprolol
Celiprolol is an investigational treatment for vascular Ehlers-Danlos syndrome. The event-driven Phase 3 DiSCOVER trial is being conducted under an FDA Special Protocol Assessment.
## Why The Stock Is Moving

The latest company update was “Zevra Therapeutics to Present at Upcoming Investor Conferences”. ZVRA changed 1.99% and closed at $12.30 on Sep 2, 2026, indicating a relatively limited closing-price reaction to this commercial update.

## Recent News
- 2026-09-02 11:30 EST — [Zevra Therapeutics to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-to-present-at-upcoming-investor-conferences-c8ffb79f) — Source: Zevra
- 2026-08-25 11:30 EST — [Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium](https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-to-present-new-long-term-real-world-data-on-miplyffa-in-niema-31aadb7b) — Source: Zevra
- 2026-08-21 20:30 EST — [Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--86661a61) — Source: Zevra
- 2026-08-05 20:05 EST — [Zevra Reports Second Quarter 2026 Financial Results and Corporate Update](https://biopharmsignal.com/news/ZVRA/zevra-reports-second-quarter-2026-financial-results-and-corporate-update-6cc97616) — Source: Zevra
- 2026-08-04 11:30 EST — [Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference](https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-to-present-at-the-canaccord-genuity-annual-growth-conference-549d8be6) — Source: Zevra